Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Apr 24, 2018 12:02pm
130 Views
Post# 27932457

RE:RE:RE:RE:RE:Pooropinion, good post, do you know Naproxen's CV profile

RE:RE:RE:RE:RE:Pooropinion, good post, do you know Naproxen's CV profile
KrispyBacon wrote: Edcando - first off i appreciate how often you post and how pro-ATE you are.  This is by no means a bashing post, but one to put a check on yours.

I think Poor is looking for a bit more scientific/factual based response, rather than just half dose = better.  That is not good enough for the FDA....

Yes, 2b results exceeded expectations, but was not directly related to cv.  Just because 2b exceeded expectations does not mean any tests they havent specifically done yet will be the same.... With that logic we could say this drug helps cure cancer as well!! (a boy can dream).

Meaningful data would be something like 10,000 patients in phase 3 took x dosage for x time and there was no significant cv change with a p value of .0001 (just for example).  


I like Edcando's points. ATB346 already does have things going for it as he points out, the lower dose is definitely one of them. I'm not bashing ATB-346 I just want to undrrstand what the FDA position is on the CV problem. Get some understanding here, know how Antibe plan to answer the questions, see the data and move closer to the "slam dunk" :)

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities